

# Harold E Bays

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2352376/publications.pdf>

Version: 2024-02-01

40  
papers

3,180  
citations

361413

20  
h-index

501196

28  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3107  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Obesity Pillars Roundtable: Obesity and South Asians. , 2022, 1, 100006.  |     | 3         |
| 2  | Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 1, 100007.  |     | 14        |
| 3  | Obesity Pillars Roundtable: Obesity and Diversity. , 2022, 1, 100008.   |     | 1         |
| 4  | Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 1, 100004.                                       |     | 37        |
| 5  | Obesity Medicine Association (OMA): Nurse practitioner & physician assistants update. , 2022, 1, 100001.  |     | 1         |
| 6  | Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology, 2022, 16, 286-297.  | 1.5 | 20        |
| 7  | Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100015.  |     | 9         |
| 8  | Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100017.  |     | 11        |
| 9  | Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100014.                                      |     | 11        |
| 10 | Obesity Pillars Roundtable: Obesity and East Asians. , 2022, 2, 100011.   |     | 1         |
| 11 | Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100018.   |     | 13        |
| 12 | Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5 |     |           |
| 13 | Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 3, 100027.  |     | 8         |
| 14 | Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 3, 100026.  |     | 22        |
| 15 | Obesity pillars roundtable: Phentermine “ Past, present, and future. , 2022, 3, 100024.   |     | 5         |
| 16 | Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. American Heart Journal, 2021, 235, 104-112.                               | 2.7 | 82        |
| 17 | Ten things to know about ten cardiovascular disease risk factors. American Journal of Preventive Cardiology, 2021, 5, 100149.   | 3.0 | 87        |
| 18 | Role of Bempedoic Acid in Clinical Practice. Cardiovascular Drugs and Therapy, 2021, 35, 853-864.   | 2.6 | 71        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Ten things to know about ten imaging studies: A preventive cardiology perspective (â€œASPC top ten) Tj ETQq1 1.0,784314,rgBT /Over   | 3.0  | 14        |
| 20 | Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American Journal of Preventive Cardiology, 2021, 8, 100278.                                    | 3.0  | 14        |
| 21 | Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European Journal of Preventive Cardiology, 2020, 27, 593-603.  | 1.8  | 224       |
| 22 | Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. Journal of Clinical Lipidology, 2020, 14, 649-659.e6.   | 1.5  | 70        |
| 23 | Licoglitflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity, 2020, 28, 870-881.   | 3.0  | 27        |
| 24 | Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine, 2019, 380, 1022-1032.  | 27.0 | 529       |
| 25 | Assessment of the 1% of Patients with Consistent &lt;âˆ15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials. Cardiovascular Drugs and Therapy, 2018, 32, 175-180.   | 2.6  | 21        |
| 26 | Lorcaserin and metabolic disease: weightâ€loss dependent and independent effects. Obesity Science and Practice, 2018, 4, 499-505.  | 1.9  | 5         |
| 27 | Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. Journal of Clinical Lipidology, 2017, 11, 450-458.e1.  | 1.5  | 28        |
| 28 | Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. Journal of Clinical Lipidology, 2017, 11, 929-937. | 1.5  | 9         |
| 29 | Alirocumab Treatment and Achievement of Nonâ€Highâ€Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. Journal of the American Heart Association, 2017, 6, .  | 3.7  | 14        |
| 30 | Liraglutide 3.0â€mg for weight management: weight-loss dependent and independent effects. Current Medical Research and Opinion, 2017, 33, 225-229.   | 1.9  | 27        |
| 31 | Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity, 2014, 22, 1042-1049.   | 3.0  | 126       |
| 32 | Adiposopathy, â€œSick Fat,â€Ockhamâ€™s Razor, and Resolution of the Obesity Paradox. Current Atherosclerosis Reports, 2014, 16, 409.   | 4.8  | 78        |
| 33 | Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating â€œSick Fatâ€Through Improving Fat Function with Antidiabetes Therapies. American Journal of Cardiology, 2012, 110, 4B-12B.   | 1.6  | 56        |
| 34 | Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Review of Cardiovascular Therapy, 2011, 9, 265-277.   | 1.5  | 25        |
| 35 | Adiposopathy. Journal of the American College of Cardiology, 2011, 57, 2461-2473.  | 2.8  | 358       |
| 36 | Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. New England Journal of Medicine, 2010, 363, 245-256.  | 27.0 | 816       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2009, 25, 671-681.  | 1.9 | 72        |
| 38 | Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 259-271.   | 0.9 | 36        |
| 39 | Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 393-404.   | 1.5 | 36        |
| 40 | A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. <i>Clinical Therapeutics</i> , 2004, 26, 1758-1773. | 2.5 | 171       |